Skip to main content
Top
Published in: Seminars in Immunopathology 1/2013

Open Access 01-01-2013 | Review

Occult HBV infection

Authors: Giovanni Raimondo, Gaia Caccamo, Roberto Filomia, Teresa Pollicino

Published in: Seminars in Immunopathology | Issue 1/2013

Login to get access

Abstract

The long-lasting persistence of hepatitis B virus (HBV) genomes in the liver (with detectable or undetectable HBV DNA in the serum) of individuals testing negative for the HBV surface antigen (HBsAg) is termed occult HBV infection (OBI). Although in a minority of cases the lack of HBsAg detection is due to infection with variant viruses unrecognized by available assays (S-escape mutants), the typical OBI is related to replication-competent HBVs strongly suppressed in their replication activity. The causes of HBV suppression are not yet well clarified, although the host’s immune surveillance and epigenetic mechanisms are likely involved. OBI is a worldwide diffused entity, but the available data of prevalence in various categories of individuals are often contrasting because of the different sensitivity and specificity of the methods used for its detection in many studies. OBI may have an impact in several different clinical contexts. In fact, it can be transmitted (i.e., through blood transfusion and liver transplantation) causing classic forms of hepatitis B in newly infected individuals. The development of an immunosuppressive status (mainly by immunotherapy or chemotherapy) may induce OBI reactivation and development of acute and often severe hepatitis. Finally, evidence suggests that OBI can favor the progression of liver fibrosis, in particular in HCV-infected patients. The possible contribution of OBI to the establishment of cirrhosis also implies its possible indirect role in the development of hepatocellular carcinoma. On the other hand, OBI may maintain most of the direct transforming properties of the overt HBV infection, such as the capacity to integrate in the host’s genome and to synthesize pro-oncogenic proteins.
Literature
1.
go back to reference (2009). EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50:227–242 (2009). EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50:227–242
2.
go back to reference Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxi A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trepo C, Villa E, Will H, Zanetti AR, Zoulim F (2008) Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49:652–657PubMedCrossRef Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxi A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trepo C, Villa E, Will H, Zanetti AR, Zoulim F (2008) Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49:652–657PubMedCrossRef
3.
go back to reference Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G (1999) Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 341:22–26PubMedCrossRef Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G (1999) Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 341:22–26PubMedCrossRef
4.
go back to reference Wands JR, Chura CM, Roll FJ, Maddrey WC (1975) Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 68:105–112PubMed Wands JR, Chura CM, Roll FJ, Maddrey WC (1975) Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 68:105–112PubMed
6.
go back to reference Thiers V, Nakajima E, Kremsdorf D, Mack D, Schellekens H, Driss F, Goudeau A, Wands J, Sninsky J, Tiollais P (1988) Transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet 2:1273–1276PubMedCrossRef Thiers V, Nakajima E, Kremsdorf D, Mack D, Schellekens H, Driss F, Goudeau A, Wands J, Sninsky J, Tiollais P (1988) Transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet 2:1273–1276PubMedCrossRef
7.
go back to reference Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC (1981) Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med 305:1067–1073PubMedCrossRef Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC (1981) Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med 305:1067–1073PubMedCrossRef
8.
go back to reference Rehermann B, Ferrari C, Pasquinelli C, Chisari FV (1996) The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2:1104–1108PubMedCrossRef Rehermann B, Ferrari C, Pasquinelli C, Chisari FV (1996) The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2:1104–1108PubMedCrossRef
9.
go back to reference Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G (2004) Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 126:102–110PubMedCrossRef Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G (2004) Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 126:102–110PubMedCrossRef
10.
go back to reference Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, Chisari FV, Rehermann B, Del PG, Fiaccadori F, Ferrari C (1996) Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 98:1185–1194PubMedCrossRef Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, Chisari FV, Rehermann B, Del PG, Fiaccadori F, Ferrari C (1996) Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 98:1185–1194PubMedCrossRef
11.
go back to reference Michalak TI, Pasquinelli C, Guilhot S, Chisari FV (1994) Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 94:907PubMedCrossRef Michalak TI, Pasquinelli C, Guilhot S, Chisari FV (1994) Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 94:907PubMedCrossRef
12.
go back to reference Kaneko S, Miller RH, Feinstone SM, Unoura M, Kobayashi K, Hattori N, Purcell RH (1989) Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay. Proc Natl Acad Sci USA 86:312–316PubMedCrossRef Kaneko S, Miller RH, Feinstone SM, Unoura M, Kobayashi K, Hattori N, Purcell RH (1989) Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay. Proc Natl Acad Sci USA 86:312–316PubMedCrossRef
13.
go back to reference Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ (1978) Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 298:1379–1383PubMedCrossRef Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ (1978) Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 298:1379–1383PubMedCrossRef
14.
go back to reference Chazouilleres O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, Ascher NL, Wright TL (1994) “Occult” hepatitis B virus as source of infection in liver transplant recipients. Lancet 343:142–146PubMedCrossRef Chazouilleres O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, Ascher NL, Wright TL (1994) “Occult” hepatitis B virus as source of infection in liver transplant recipients. Lancet 343:142–146PubMedCrossRef
15.
go back to reference Brechot C, Hadchouel M, Scotto J, Fonck M, Potet F, Vyas GN, Tiollais P (1981) State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases. Proc Natl Acad Sci USA 78:3906–3910PubMedCrossRef Brechot C, Hadchouel M, Scotto J, Fonck M, Potet F, Vyas GN, Tiollais P (1981) State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases. Proc Natl Acad Sci USA 78:3906–3910PubMedCrossRef
16.
go back to reference Pollicino T, Saitta C, Raimondo G (2011) Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis 32:1122–1132PubMedCrossRef Pollicino T, Saitta C, Raimondo G (2011) Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis 32:1122–1132PubMedCrossRef
17.
go back to reference Ganem D, Prince AM (2004) Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med 350:1118–1129PubMedCrossRef Ganem D, Prince AM (2004) Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med 350:1118–1129PubMedCrossRef
18.
go back to reference Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M (2009) Control of cccDNA function in hepatitis B virus infection. J Hepatol 51:581–592PubMedCrossRef Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M (2009) Control of cccDNA function in hepatitis B virus infection. J Hepatol 51:581–592PubMedCrossRef
19.
go back to reference Zoulim F (2005) New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 42:302–308PubMedCrossRef Zoulim F (2005) New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 42:302–308PubMedCrossRef
20.
go back to reference Raimondo G, Pollicino T, Cacciola I, Squadrito G (2007) Occult hepatitis B virus infection. J Hepatol 46:160–170PubMedCrossRef Raimondo G, Pollicino T, Cacciola I, Squadrito G (2007) Occult hepatitis B virus infection. J Hepatol 46:160–170PubMedCrossRef
21.
go back to reference Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, Levrero M, Raimondo G (2007) Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 45:277–285PubMedCrossRef Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, Levrero M, Raimondo G (2007) Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 45:277–285PubMedCrossRef
22.
go back to reference Mulrooney-Cousins PM, Michalak TI (2007) Persistent occult hepatitis B virus infection: experimental findings and clinical implications. World J Gastroenterol 13:5682–5686PubMed Mulrooney-Cousins PM, Michalak TI (2007) Persistent occult hepatitis B virus infection: experimental findings and clinical implications. World J Gastroenterol 13:5682–5686PubMed
23.
go back to reference Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, Hung IF, Yuen MF (2011) Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 54:829–836PubMedCrossRef Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, Hung IF, Yuen MF (2011) Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 54:829–836PubMedCrossRef
24.
go back to reference Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP (1998) Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 27:1736–1742PubMedCrossRef Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP (1998) Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 27:1736–1742PubMedCrossRef
25.
go back to reference Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di VP, Giuberti T, Orlandini A, Raffa G, Pollicino T, Raimondo G, Ferrari C, Missale G (2008) The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 134:1470–1481PubMedCrossRef Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di VP, Giuberti T, Orlandini A, Raffa G, Pollicino T, Raimondo G, Ferrari C, Missale G (2008) The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 134:1470–1481PubMedCrossRef
26.
go back to reference Bes M, Vargas V, Piron M, Casamitjana N, Esteban JI, Vilanova N, Pinacho A, Quer J, Puig L, Guardia J, Sauleda S (2011) T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. J Hepatol Bes M, Vargas V, Piron M, Casamitjana N, Esteban JI, Vilanova N, Pinacho A, Quer J, Puig L, Guardia J, Sauleda S (2011) T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. J Hepatol
27.
go back to reference Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI (2009) Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol 81:441–445PubMedCrossRef Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI (2009) Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol 81:441–445PubMedCrossRef
28.
go back to reference Martin CM, Welge JA, Shire NJ, Shata MT, Sherman KE, Blackard JT (2009) Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals. Cytokine 47:194–198PubMedCrossRef Martin CM, Welge JA, Shire NJ, Shata MT, Sherman KE, Blackard JT (2009) Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals. Cytokine 47:194–198PubMedCrossRef
29.
go back to reference Guidotti LG, Chisari FV (2001) Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 19:65–91PubMedCrossRef Guidotti LG, Chisari FV (2001) Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 19:65–91PubMedCrossRef
30.
go back to reference Lucifora J, Durantel D, Testoni B, Hantz O, Levrero M, Zoulim F (2010) Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology 51:63–72PubMedCrossRef Lucifora J, Durantel D, Testoni B, Hantz O, Levrero M, Zoulim F (2010) Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology 51:63–72PubMedCrossRef
31.
32.
go back to reference Takacs M, Banati F, Koroknai A, Segesdi J, Salamon D, Wolf H, Niller HH, Minarovits J (2010) Epigenetic regulation of latent Epstein–Barr virus promoters. Biochim Biophys Acta 1799:228–235PubMedCrossRef Takacs M, Banati F, Koroknai A, Segesdi J, Salamon D, Wolf H, Niller HH, Minarovits J (2010) Epigenetic regulation of latent Epstein–Barr virus promoters. Biochim Biophys Acta 1799:228–235PubMedCrossRef
33.
go back to reference Bloom DC, Giordani NV, Kwiatkowski DL (2010) Epigenetic regulation of latent HSV-1 gene expression. Biochim Biophys Acta 1799:246–256PubMedCrossRef Bloom DC, Giordani NV, Kwiatkowski DL (2010) Epigenetic regulation of latent HSV-1 gene expression. Biochim Biophys Acta 1799:246–256PubMedCrossRef
34.
go back to reference Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, Levrero M (2006) Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 130:823–837PubMedCrossRef Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, Levrero M (2006) Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 130:823–837PubMedCrossRef
35.
go back to reference Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F (2004) Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126:1750–1758PubMedCrossRef Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F (2004) Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126:1750–1758PubMedCrossRef
36.
go back to reference Cougot D, Allemand E, Riviere L, Benhenda S, Duroure K, Levillayer F, Muchardt C, Buendia MA, Neuveut C (2012) Inhibition of PP1 phosphatase activity by HBx: A mechanism for the activation of hepatitis B virus transcription. Sci Signal 5, ra1 Cougot D, Allemand E, Riviere L, Benhenda S, Duroure K, Levillayer F, Muchardt C, Buendia MA, Neuveut C (2012) Inhibition of PP1 phosphatase activity by HBx: A mechanism for the activation of hepatitis B virus transcription. Sci Signal 5, ra1
37.
go back to reference Belloni L, Pollicino T, De NF, Guerrieri F, Raffa G, Fanciulli M, Raimondo G, Levrero M (2009) Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci USA 106:19975–19979PubMed Belloni L, Pollicino T, De NF, Guerrieri F, Raffa G, Fanciulli M, Raimondo G, Levrero M (2009) Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci USA 106:19975–19979PubMed
38.
go back to reference Klass CM, Krug LT, Pozharskaya VP, Offermann MK (2005) The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood 105:4028–4034PubMedCrossRef Klass CM, Krug LT, Pozharskaya VP, Offermann MK (2005) The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood 105:4028–4034PubMedCrossRef
39.
go back to reference Feng WH, Kenney SC (2006) Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 66:8762–8769PubMedCrossRef Feng WH, Kenney SC (2006) Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 66:8762–8769PubMedCrossRef
40.
go back to reference Grewal J, Dellinger CA, Yung WK (2007) Fatal reactivation of hepatitis B with temozolomide. N Engl J Med 356:1591–1592PubMedCrossRef Grewal J, Dellinger CA, Yung WK (2007) Fatal reactivation of hepatitis B with temozolomide. N Engl J Med 356:1591–1592PubMedCrossRef
41.
go back to reference Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M (2012) IFN-á inhibits HBV transcription and replication by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest In Press Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M (2012) IFN-á inhibits HBV transcription and replication by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest In Press
42.
go back to reference Vivekanandan P, Thomas D, Torbenson M (2009) Methylation regulates hepatitis B viral protein expression. J Infect Dis 199:1286–1291PubMedCrossRef Vivekanandan P, Thomas D, Torbenson M (2009) Methylation regulates hepatitis B viral protein expression. J Infect Dis 199:1286–1291PubMedCrossRef
43.
go back to reference Kaur P, Paliwal A, Durantel D, Hainaut P, Scoazec JY, Zoulim F, Chemin I, Herceg Z (2010) DNA methylation of hepatitis B virus (HBV) genome associated with the development of hepatocellular carcinoma and occult HBV infection. J Infect Dis 202:700–704PubMedCrossRef Kaur P, Paliwal A, Durantel D, Hainaut P, Scoazec JY, Zoulim F, Chemin I, Herceg Z (2010) DNA methylation of hepatitis B virus (HBV) genome associated with the development of hepatocellular carcinoma and occult HBV infection. J Infect Dis 202:700–704PubMedCrossRef
44.
go back to reference El CM, Candotti D, Crowther RA, Allain JP (2010) Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology 52:1600–1610CrossRef El CM, Candotti D, Crowther RA, Allain JP (2010) Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology 52:1600–1610CrossRef
45.
go back to reference Vivekanandan P, Kannangai R, Ray SC, Thomas DL, Torbenson M (2008) Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis 46:1227–1236PubMedCrossRef Vivekanandan P, Kannangai R, Ray SC, Thomas DL, Torbenson M (2008) Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis 46:1227–1236PubMedCrossRef
46.
go back to reference Pollicino T, Amaddeo G, Restuccia A, Raffa, G, Alibrandi A, Cutroneo G, Favaloro A, Maimone, S, Squadrito G, Raimondo G (2012) Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology In Press Pollicino T, Amaddeo G, Restuccia A, Raffa, G, Alibrandi A, Cutroneo G, Favaloro A, Maimone, S, Squadrito G, Raimondo G (2012) Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology In Press
47.
go back to reference Raimondo G, Cacciamo G, Saitta C (2005) Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease? Ann Hepatol 4:100–106PubMed Raimondo G, Cacciamo G, Saitta C (2005) Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease? Ann Hepatol 4:100–106PubMed
48.
go back to reference Bellecave P, Gouttenoire J, Gajer M, Brass V, Koutsoudakis G, Blum HE, Bartenschlager R, Nassal M, Moradpour D (2009) Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology 50:46–55PubMedCrossRef Bellecave P, Gouttenoire J, Gajer M, Brass V, Koutsoudakis G, Blum HE, Bartenschlager R, Nassal M, Moradpour D (2009) Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology 50:46–55PubMedCrossRef
49.
go back to reference McClary H, Koch R, Chisari FV, Guidotti LG (2000) Inhibition of hepatitis B virus replication during schistosoma mansoni infection in transgenic mice. J Exp Med 192:289–294PubMedCrossRef McClary H, Koch R, Chisari FV, Guidotti LG (2000) Inhibition of hepatitis B virus replication during schistosoma mansoni infection in transgenic mice. J Exp Med 192:289–294PubMedCrossRef
50.
go back to reference Hollinger FB (2008) Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 48:1001–1026PubMedCrossRef Hollinger FB (2008) Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 48:1001–1026PubMedCrossRef
51.
go back to reference Candotti D, Allain JP (2009) Transfusion-transmitted hepatitis B virus infection. J Hepatol 51:798–809PubMedCrossRef Candotti D, Allain JP (2009) Transfusion-transmitted hepatitis B virus infection. J Hepatol 51:798–809PubMedCrossRef
52.
go back to reference Shetty K, Hussain M, Nei L, Reddy KR, Lok AS (2008) Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl 14:534–540PubMedCrossRef Shetty K, Hussain M, Nei L, Reddy KR, Lok AS (2008) Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl 14:534–540PubMedCrossRef
53.
go back to reference Shouval D (2008) What is the clinical significance of the high prevalence of occult hepatitis B in US liver transplant patients with chronic hepatitis C? Liver Transpl 14:418–419PubMedCrossRef Shouval D (2008) What is the clinical significance of the high prevalence of occult hepatitis B in US liver transplant patients with chronic hepatitis C? Liver Transpl 14:418–419PubMedCrossRef
54.
go back to reference Georgiadou SP, Zachou K, Liaskos C, Gabeta S, Rigopoulou EI, Dalekos GN (2009) Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver Int 29:434–442PubMedCrossRef Georgiadou SP, Zachou K, Liaskos C, Gabeta S, Rigopoulou EI, Dalekos GN (2009) Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver Int 29:434–442PubMedCrossRef
55.
go back to reference Torbenson M, Kannangai R, Astemborski J, Strathdee SA, Vlahov D, Thomas DL (2004) High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 39:51–57PubMedCrossRef Torbenson M, Kannangai R, Astemborski J, Strathdee SA, Vlahov D, Thomas DL (2004) High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 39:51–57PubMedCrossRef
56.
go back to reference Toyoda H, Hayashi K, Murakami Y, Honda T, Katano Y, Nakano I, Goto H, Kumada T, Takamatsu J (2004) Prevalence and clinical implications of occult hepatitis B viral infection in hemophilia patients in Japan. J Med Virol 73:195–199PubMedCrossRef Toyoda H, Hayashi K, Murakami Y, Honda T, Katano Y, Nakano I, Goto H, Kumada T, Takamatsu J (2004) Prevalence and clinical implications of occult hepatitis B viral infection in hemophilia patients in Japan. J Med Virol 73:195–199PubMedCrossRef
57.
go back to reference Yakaryilmaz F, Gurbuz OA, Guliter S, Mert A, Songur Y, Karakan T, Keles H (2006) Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail 28:729–735PubMedCrossRef Yakaryilmaz F, Gurbuz OA, Guliter S, Mert A, Songur Y, Karakan T, Keles H (2006) Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail 28:729–735PubMedCrossRef
58.
go back to reference Sav T, Gursoy S, Torun E, Sav NM, Unal A, Oymak O, Utas C (2010) Occult HBV infection in continuous ambulatory peritoneal dialysis and hemodialysis patients. Ren Fail 32:74–77PubMedCrossRef Sav T, Gursoy S, Torun E, Sav NM, Unal A, Oymak O, Utas C (2010) Occult HBV infection in continuous ambulatory peritoneal dialysis and hemodialysis patients. Ren Fail 32:74–77PubMedCrossRef
59.
go back to reference Fabrizi F, Messa PG, Lunghi G, Aucella F, Bisegna S, Mangano S, Villa M, Barbisoni F, Rusconi E, Martin P (2005) Occult hepatitis B virus infection in dialysis patients: a multicentre survey. Aliment Pharmacol Ther 21:1341–1347PubMedCrossRef Fabrizi F, Messa PG, Lunghi G, Aucella F, Bisegna S, Mangano S, Villa M, Barbisoni F, Rusconi E, Martin P (2005) Occult hepatitis B virus infection in dialysis patients: a multicentre survey. Aliment Pharmacol Ther 21:1341–1347PubMedCrossRef
60.
go back to reference Di SM, Volpe A, Stallone G, Tartaglia L, Prato R, Martinelli D, Pastore G, Gesualdo L, Fiore JR (2009) Occult HBV infection in hemodialysis setting is marked by presence of isolated antibodies to HBcAg and HCV. J Nephrol 22:381–386 Di SM, Volpe A, Stallone G, Tartaglia L, Prato R, Martinelli D, Pastore G, Gesualdo L, Fiore JR (2009) Occult HBV infection in hemodialysis setting is marked by presence of isolated antibodies to HBcAg and HCV. J Nephrol 22:381–386
61.
go back to reference Raffa G, Maimone S, Cargnel A, Santantonio T, Antonucci G, Massari M, Schiavini M, Caccamo G, Pollicino T, Raimondo G (2007) Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C. AIDS 21:2171–2175PubMedCrossRef Raffa G, Maimone S, Cargnel A, Santantonio T, Antonucci G, Massari M, Schiavini M, Caccamo G, Pollicino T, Raimondo G (2007) Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C. AIDS 21:2171–2175PubMedCrossRef
62.
go back to reference Minuk GY, Sun DF, Uhanova J, Zhang M, Caouette S, Nicolle LE, Gutkin A, Doucette K, Martin B, Giulivi A (2005) Occult hepatitis B virus infection in a North American community-based population. J Hepatol 42:480–485PubMedCrossRef Minuk GY, Sun DF, Uhanova J, Zhang M, Caouette S, Nicolle LE, Gutkin A, Doucette K, Martin B, Giulivi A (2005) Occult hepatitis B virus infection in a North American community-based population. J Hepatol 42:480–485PubMedCrossRef
63.
go back to reference Kim SM, Lee KS, Park CJ, Lee JY, Kim KH, Park JY, Lee JH, Kim HY, Yoo JY, Jang MK (2007) Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. J Infect 54:185–191PubMedCrossRef Kim SM, Lee KS, Park CJ, Lee JY, Kim KH, Park JY, Lee JH, Kim HY, Yoo JY, Jang MK (2007) Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. J Infect 54:185–191PubMedCrossRef
64.
go back to reference Hui CK, Sun J, Au WY, Lie AK, Yueng YH, Zhang HY, Lee NP, Hou JL, Liang R, Lau GK (2005) Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 42:813–819PubMedCrossRef Hui CK, Sun J, Au WY, Lie AK, Yueng YH, Zhang HY, Lee NP, Hou JL, Liang R, Lau GK (2005) Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 42:813–819PubMedCrossRef
65.
go back to reference Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, Di VG, Scisca C, Squadrito G, Pollicino T (2008) Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 48:743–746PubMedCrossRef Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, Di VG, Scisca C, Squadrito G, Pollicino T (2008) Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 48:743–746PubMedCrossRef
66.
go back to reference Stramer SL, Wend U, Candotti D, Foster GA, Hollinger FB, Dodd RY, Allain JP, Gerlich W (2011) Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 364:236–247PubMedCrossRef Stramer SL, Wend U, Candotti D, Foster GA, Hollinger FB, Dodd RY, Allain JP, Gerlich W (2011) Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 364:236–247PubMedCrossRef
67.
go back to reference Hollinger FB, Sood G (2010) Occult hepatitis B virus infection: a covert operation. J Viral Hepat 17:1–15PubMedCrossRef Hollinger FB, Sood G (2010) Occult hepatitis B virus infection: a covert operation. J Viral Hepat 17:1–15PubMedCrossRef
68.
go back to reference Allain JP, Cox L (2011) Challenges in hepatitis B detection among blood donors. Curr Opin Hematol 18:461–466PubMedCrossRef Allain JP, Cox L (2011) Challenges in hepatitis B detection among blood donors. Curr Opin Hematol 18:461–466PubMedCrossRef
69.
go back to reference Belloni L (1972) Morgagni-Reaumur correspondence in the Public Library of Forli. Gesnerus 29:225–254PubMed Belloni L (1972) Morgagni-Reaumur correspondence in the Public Library of Forli. Gesnerus 29:225–254PubMed
70.
go back to reference Kannangai R, Vivekanandan P, Netski D, Mehta S, Kirk GD, Thomas DL, Torbenson M (2007) Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. J Clin Virol 39:101–105PubMedCrossRef Kannangai R, Vivekanandan P, Netski D, Mehta S, Kirk GD, Thomas DL, Torbenson M (2007) Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. J Clin Virol 39:101–105PubMedCrossRef
71.
go back to reference Chemin I, Guillaud O, Queyron PC, Trepo C (2009) Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. J Hepatol 51:824–825PubMedCrossRef Chemin I, Guillaud O, Queyron PC, Trepo C (2009) Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. J Hepatol 51:824–825PubMedCrossRef
72.
go back to reference Komiya Y, Katayama K, Yugi H, Mizui M, Matsukura H, Tomoguri T, Miyakawa Y, Tabuchi A, Tanaka J, Yoshizawa H (2008) Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion 48:286–294PubMed Komiya Y, Katayama K, Yugi H, Mizui M, Matsukura H, Tomoguri T, Miyakawa Y, Tabuchi A, Tanaka J, Yoshizawa H (2008) Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion 48:286–294PubMed
73.
go back to reference Allain JP, Belkhiri D, Vermeulen M, Crookes R, Cable R, Amiri A, Reddy R, Bird A, Candotti D (2009) Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology 49:1868–1876PubMedCrossRef Allain JP, Belkhiri D, Vermeulen M, Crookes R, Cable R, Amiri A, Reddy R, Bird A, Candotti D (2009) Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology 49:1868–1876PubMedCrossRef
74.
go back to reference Cheung CK, Lo CM, Man K, Lau GK (2010) Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis. Liver Transpl 16:1314–1323PubMedCrossRef Cheung CK, Lo CM, Man K, Lau GK (2010) Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis. Liver Transpl 16:1314–1323PubMedCrossRef
75.
go back to reference Cholongitas E, Papatheodoridis GV, Burroughs AK (2010) Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 52:272–279PubMedCrossRef Cholongitas E, Papatheodoridis GV, Burroughs AK (2010) Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 52:272–279PubMedCrossRef
76.
go back to reference Coffin CS, Mulrooney-Cousins PM, van MG, Roberts JP, Michalak TI, Terrault NA (2011) Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl 17:955–962PubMedCrossRef Coffin CS, Mulrooney-Cousins PM, van MG, Roberts JP, Michalak TI, Terrault NA (2011) Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl 17:955–962PubMedCrossRef
77.
go back to reference Toniutto P, Minisini R, Fabris C, De FT, Marangoni F, Burlone M, Avellini C, Bitetto D, Fornasiere E, Fumolo E, Baccarani U, Pirisi M (2009) Occult hepatitis B virus infection in liver transplant recipients with recurrent hepatitis C: relationship with donor age and fibrosis progression. Clin Transplant 23:184–190PubMedCrossRef Toniutto P, Minisini R, Fabris C, De FT, Marangoni F, Burlone M, Avellini C, Bitetto D, Fornasiere E, Fumolo E, Baccarani U, Pirisi M (2009) Occult hepatitis B virus infection in liver transplant recipients with recurrent hepatitis C: relationship with donor age and fibrosis progression. Clin Transplant 23:184–190PubMedCrossRef
78.
go back to reference Kusumoto S, Tanaka Y, Mizokami M, Ueda R (2009) Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 90:13–23PubMedCrossRef Kusumoto S, Tanaka Y, Mizokami M, Ueda R (2009) Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 90:13–23PubMedCrossRef
79.
go back to reference Lalazar G, Rund D, Shouval D (2007) Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 136:699–712PubMedCrossRef Lalazar G, Rund D, Shouval D (2007) Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 136:699–712PubMedCrossRef
80.
go back to reference Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519–528PubMed Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519–528PubMed
81.
go back to reference Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B, Di Marco V, Fabrizi F, Fagiuoli S, Grossi P, Lampertico P, Meliconi R, Mangia A, Puoti M, Raimondo G, Smedile A (2007) Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 39:397–408PubMedCrossRef Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B, Di Marco V, Fabrizi F, Fagiuoli S, Grossi P, Lampertico P, Meliconi R, Mangia A, Puoti M, Raimondo G, Smedile A (2007) Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 39:397–408PubMedCrossRef
82.
go back to reference Ritchie D, Piekarz RL, Blombery P, Karai LJ, Pittaluga S, Jaffe ES, Raffeld M, Janik JE, Prince HM, Bates SE (2009) Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica 94:1618–1622PubMedCrossRef Ritchie D, Piekarz RL, Blombery P, Karai LJ, Pittaluga S, Jaffe ES, Raffeld M, Janik JE, Prince HM, Bates SE (2009) Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica 94:1618–1622PubMedCrossRef
83.
go back to reference Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY (2010) Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 89:255–262PubMedCrossRef Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY (2010) Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 89:255–262PubMedCrossRef
84.
go back to reference Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK (2009) Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605–611PubMedCrossRef Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK (2009) Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605–611PubMedCrossRef
85.
go back to reference Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, Kondo T, Toyoshima N, Ota S, Kobayashi S, Hige S, Toubai T, Tanaka J, Imamura M, Asaka M (2005) Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 79:616–619PubMedCrossRef Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, Kondo T, Toyoshima N, Ota S, Kobayashi S, Hige S, Toubai T, Tanaka J, Imamura M, Asaka M (2005) Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 79:616–619PubMedCrossRef
86.
go back to reference Vigano M, Vener C, Lampertico P, Annaloro C, Pichoud C, Zoulim F, Facchetti F, Poli F, Scalamogna M, Deliliers GL, Colombo M (2011) Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant 46:125–131PubMedCrossRef Vigano M, Vener C, Lampertico P, Annaloro C, Pichoud C, Zoulim F, Facchetti F, Poli F, Scalamogna M, Deliliers GL, Colombo M (2011) Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant 46:125–131PubMedCrossRef
87.
go back to reference Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, Iodice V, Sagnelli C, Stanzione M, Capoluongo N, Pasquale G, Sagnelli E (2011) Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol 83:1909–1916PubMedCrossRef Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, Iodice V, Sagnelli C, Stanzione M, Capoluongo N, Pasquale G, Sagnelli E (2011) Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol 83:1909–1916PubMedCrossRef
88.
go back to reference Sanchez MJ, Buti M, Homs M, Palacios A, Rodriguez-Frias F, Esteban R (2009) Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. J Hepatol 51:1091–1096PubMedCrossRef Sanchez MJ, Buti M, Homs M, Palacios A, Rodriguez-Frias F, Esteban R (2009) Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. J Hepatol 51:1091–1096PubMedCrossRef
89.
go back to reference Blackberg J, Kidd-Ljunggren K (2000) Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 33:992–997PubMedCrossRef Blackberg J, Kidd-Ljunggren K (2000) Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 33:992–997PubMedCrossRef
90.
go back to reference Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, Omura M, Hikiji K, Kato M (2003) Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 37:1172–1179PubMedCrossRef Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, Omura M, Hikiji K, Kato M (2003) Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 37:1172–1179PubMedCrossRef
91.
go back to reference Raimondo G, Pollicino T, Squadrito G (2005) What is the clinical impact of occult hepatitis B virus infection? Lancet 365:638–640PubMed Raimondo G, Pollicino T, Squadrito G (2005) What is the clinical impact of occult hepatitis B virus infection? Lancet 365:638–640PubMed
92.
go back to reference Brechot C (2004) Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 127:S56–S61PubMedCrossRef Brechot C (2004) Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 127:S56–S61PubMedCrossRef
93.
go back to reference Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, Chen Z (2012) Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int 32:231–240PubMedCrossRef Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, Chen Z (2012) Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int 32:231–240PubMedCrossRef
94.
go back to reference Corradini E, Ferrara F, Pollicino T, Vegetti A, Abbati GL, Losi L, Raimondo G, Pietrangelo A (2007) Disease progression and liver cancer in the ferroportin disease. Gut 56:1030–1032PubMedCrossRef Corradini E, Ferrara F, Pollicino T, Vegetti A, Abbati GL, Losi L, Raimondo G, Pietrangelo A (2007) Disease progression and liver cancer in the ferroportin disease. Gut 56:1030–1032PubMedCrossRef
95.
go back to reference Fwu CW, Chien YC, Kirk GD, Nelson KE, You SL, Kuo HS, Feinleib M, Chen CJ (2009) Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study. J Natl Cancer Inst 101:1019–1027PubMedCrossRef Fwu CW, Chien YC, Kirk GD, Nelson KE, You SL, Kuo HS, Feinleib M, Chen CJ (2009) Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study. J Natl Cancer Inst 101:1019–1027PubMedCrossRef
96.
go back to reference Fwu CW, Chien YC, You SL, Nelson KE, Kirk GD, Kuo HS, Feinleib M, Chen CJ (2011) Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: a cohort study of parous women in Taiwan. Hepatology 53:1217–1225PubMedCrossRef Fwu CW, Chien YC, You SL, Nelson KE, Kirk GD, Kuo HS, Feinleib M, Chen CJ (2011) Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: a cohort study of parous women in Taiwan. Hepatology 53:1217–1225PubMedCrossRef
97.
go back to reference Marcucci F, Mele A, Spada E, Candido A, Bianco E, Pulsoni A, Chionne P, Madonna E, Cotichini R, Barbui A, De RA, Dore F, Iannitto E, Liso V, Martino B, Montanaro M, Pagano L, Musto P, Rapicetta M (2006) High prevalence of hepatitis B virus infection in B-cell non-Hodgkin’s lymphoma. Haematologica 91:554–557PubMed Marcucci F, Mele A, Spada E, Candido A, Bianco E, Pulsoni A, Chionne P, Madonna E, Cotichini R, Barbui A, De RA, Dore F, Iannitto E, Liso V, Martino B, Montanaro M, Pagano L, Musto P, Rapicetta M (2006) High prevalence of hepatitis B virus infection in B-cell non-Hodgkin’s lymphoma. Haematologica 91:554–557PubMed
98.
go back to reference Tanaka M, Tanaka H, Tsukuma H, Ioka A, Oshima A, Nakahara T (2010) Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus. J Viral Hepat 17:742–748PubMedCrossRef Tanaka M, Tanaka H, Tsukuma H, Ioka A, Oshima A, Nakahara T (2010) Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus. J Viral Hepat 17:742–748PubMedCrossRef
99.
go back to reference Perumal V, Wang J, Thuluvath P, Choti M, Torbenson M (2006) Hepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United States. Hum Pathol 37:1211–1216PubMedCrossRef Perumal V, Wang J, Thuluvath P, Choti M, Torbenson M (2006) Hepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United States. Hum Pathol 37:1211–1216PubMedCrossRef
100.
go back to reference Rossi D, Sala L, Minisini R, Fabris C, Falleti E, Cerri M, Burlone ME, Toniutto P, Gaidano G, Pirisi M (2009) Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. Leuk Lymphoma 50:604–611PubMedCrossRef Rossi D, Sala L, Minisini R, Fabris C, Falleti E, Cerri M, Burlone ME, Toniutto P, Gaidano G, Pirisi M (2009) Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. Leuk Lymphoma 50:604–611PubMedCrossRef
Metadata
Title
Occult HBV infection
Authors
Giovanni Raimondo
Gaia Caccamo
Roberto Filomia
Teresa Pollicino
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Seminars in Immunopathology / Issue 1/2013
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-012-0327-7

Other articles of this Issue 1/2013

Seminars in Immunopathology 1/2013 Go to the issue